1. bookVolume 49 (2015): Issue 1 (March 2015)
Journal Details
License
Format
Journal
First Published
30 Apr 2007
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Mild hyperthermia influence on Herceptin® properties

Published Online: 03 Mar 2015
Page range: 41 - 49
Received: 17 Aug 2014
Accepted: 24 Oct 2014
Journal Details
License
Format
Journal
First Published
30 Apr 2007
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Background. Mild hyperthermia (mHT) increases the tumor perfusion and vascular permeability, and reduces the interstitial fluid pressure, resulting in better intra-tumoral bioavailability of low molecular weight drugs. This approach is potentially also attractive for delivery of therapeutic macromolecules, such as antibodies. Here, we investigated the effects of mHT on the stability, immunological and pharmacological properties of Herceptin®, a clinically approved antibody, targeting the human epidermal growth factor receptor 2 (HER-2) overexpressed in breast cancer.

Keywords

1. Ferlay J, Steliarova-Foucher E , Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.Search in Google Scholar

2. Arteaga CL, Sliwkowski MX, Osb orne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.Search in Google Scholar

3. Eroles P, Bosch A, Perez-Fidal go JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38: 698-707.Search in Google Scholar

4. Yardley DA, Tripathy D, Brufsk y AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 2014; 110: 2756-64.Search in Google Scholar

5. Hudis CA. Trastuzumab-mechanis m of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.Search in Google Scholar

6. Sliwkowski MX, Mellman I. Anti body therapeutics in cancer. Science 2013; 341: 1192-8.Search in Google Scholar

7. Scaltriti M, Verma C, Guzman M , Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28: 803-14.Search in Google Scholar

8. Klapper LN, Waterman H, Sela M , Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000; 60: 3384-8.Search in Google Scholar

9. Clynes RA, Towers TL, Presta L G, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.Search in Google Scholar

10. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6: 2065-72.Search in Google Scholar

11. Izumi Y, Xu L, di Tomaso E, Fu kumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.Search in Google Scholar

12. Li L, ten Hagen TL, Bolkestein M, Gasselhuber A, Yatvin J, van Rhoon GC, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013; 167: 130-7.Search in Google Scholar

13. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-95.Search in Google Scholar

14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.Search in Google Scholar

15. Friedl J, Turner E, Alexander HR, Jr. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int J Oncol 2003; 23: 611-6.Search in Google Scholar

16. Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 2010; 76: 998-1004.Search in Google Scholar

17. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003; 2: 1113-20.Search in Google Scholar

18. Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012; 18: 113-9.Search in Google Scholar

19. Jain RK. Physiological barrier s to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814s-9s.Search in Google Scholar

20. Jain RK. Vascular and intersti tial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253-66.Search in Google Scholar

21. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-032.Search in Google Scholar

22. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008; 14: 2171-9.Search in Google Scholar

23. Cho CH, Sreenivasa G, Plotkin M, Pietsch H, Wust P, Ludemann L. Tumour perfusion assessment during regional hyperthermia treatment: comparison of temperature probe measurement with H(2)(15)O-PET perfusion. Int J Hyperthermia 2010; 26: 404-11.Search in Google Scholar

24. Song CW. Effect of local hyper thermia on blood flow and microenvironment: a review. Cancer Res 1984; 44: 4721s-30s.Search in Google Scholar

25. Song CW, Park H, Griffin RJ. I mprovement of tumor oxygenation by mild hyperthermia. Radiat Res 2001; 155: 515-28.Search in Google Scholar

26. Kirui DK, Koay EJ, Guo X, Cris tini V, Shen H, Ferrari M. Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport. Nanomedicine 2014; 10: 1487-96.Search in Google Scholar

27. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61: 3027-32.Search in Google Scholar

28. Cope DA, Dewhirst MW, Friedman HS, Bigner DD, Zalutsky MR. Enhanced delivery of a monoclonal antibody F(ab’)2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 1990; 50: 1803-9.Search in Google Scholar

29. Kong G, Dewhirst MW. Hyperther mia and liposomes. Int J Hyperthermia 1999; 15: 345-70.Search in Google Scholar

30. Gridley DS, Ewart KL, Cao JD, Stickney DR. Hyperthermia enhances localization of 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res 1991; 51: 1515-20.Search in Google Scholar

31. Kinuya S, Yokoyama K, Hiramats u T, Tega H, Tanaka K, Konishi S, et al. Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts. Cancer Lett 1999; 140: 209-18.Search in Google Scholar

32. Wong JY, Mivechi NF, Paxton RJ , Williams LE, Beatty BG, Beatty JD, et al. The effects of hyperthermia on tumor carcinoembryonic antigen expression. Int J Radiat Oncol Biol Phys 1989; 17: 803-8.Search in Google Scholar

33. Demeule B, Gurny R, Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 2007; 329: 37-45.Search in Google Scholar

34. Cudd A, Arvinte T, Das RE, Chi nni C, MacIntyre I. Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 1995; 84: 717-9.Search in Google Scholar

35. Pickl M, Ries CH. Comparison o f 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28: 461-8.Search in Google Scholar

36. Hosono MN, Hosono M, Endo K, U eda R, Onoyama Y. Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J Nucl Med 1994; 35: 504-9.Search in Google Scholar

37. Kramer-Marek G, Gijsen M, Kies ewetter DO, Bennett R, Roxanis I, Zielinski R, et al. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med 2012; 53: 629-37.Search in Google Scholar

38. Gijsen M, King P, Perera T, Pa rker PJ, Harris AL, Larijani B, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010; 8: e1000563.Search in Google Scholar

39. Ishikawa T, Ito T, Endo R, Nak agawa K, Sawa E, Wakamatsu K. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol Pharm Bull 2010; 33: 1413-7.Search in Google Scholar

40. Landon CD, Park JY, Needham D, Dewhirst MW. Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J 2011; 3: 38-64.Search in Google Scholar

41. Goldberg SN, Gazelle GS, Muell er PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000; 174: 323-31.Search in Google Scholar

42. Bucciantini M, Giannoni E, Chi ti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-11.Search in Google Scholar

43. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20 (Suppl 6): vi3-9.Search in Google Scholar

44. Hauck ML, Dewhirst MW, Zalutsky MR. The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Nucl Med Biol 1996; 23: 551-7.Search in Google Scholar

45. Hauck ML, Larsen RH, Welsh PC, Zalutsky MR. Cytotoxicity of alpha-particleemitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. Br J Cancer 1998; 77: 753-9.Search in Google Scholar

46. Koay DC, Zerillo C, Narayan M, Harris LN, DiGiovanna MP. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Res 2010; 12: R62.Search in Google Scholar

47. Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release 2013; 169: 112-25.Search in Google Scholar

48. Hauck ML, Zalutsky MR. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. Int J Hyperthermia 2005; 21: 1-11.Search in Google Scholar

49. Escoffre JM, Novell A, de Smet M, Bouakaz A. Focused ultrasound mediated drug delivery from temperature-sensitive liposomes: in-vitro characterization and validation. Phys Med Biol 2013; 58: 8135-51. Search in Google Scholar

Plan your remote conference with Sciendo